---
figid: PMC7563273__jcm-09-02934-g003
figtitle: Targeting the PI3K/Akt/mTOR pathway in AML
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Streptomyces hygroscopicus
organisms_ner:
- Homo sapiens
- Rattus norvegicus
- Mus musculus
- Drosophila melanogaster
pmcid: PMC7563273
filename: jcm-09-02934-g003.jpg
figlink: pmc/articles/PMC7563273/figure/jcm-09-02934-f003/
number: F3
caption: Targeting the PI3K/Akt/mTOR pathway in AML. The PI3K/Akt/mTOR pathway is
  commonly dysregulated in AML caused by mutations in membrane-bound proteins such
  as receptor tyrosine kinases (RTKs) and small GTPase Ras. Activating mutations in
  fms-like tyrosine kinase 3 (FLT3), such as the FLT3-internal tandem duplication
  (FLT3-ITD), are an important mechanism leading to dysregulation of PI3K/Akt/mTOR
  signaling. The ITD mutation causes ligand-independent activation of the FLT3 receptor,
  leading to constitutive activation of the PI3K/Akt/mTOR pathway. Numerous small-molecule
  inhibitors of this pathway include FLT3 inhibitors (FLT3i), dual PI3K/mTORi, allosteric
  mTORi, pan-class I and isoform-specific PI3Ki, ATP-competitive and allosteric Akti,
  and ATP-competitive mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) inhibitors
  (mTORC1i and mTORC2i). The red arrow indicates elevated Akt phosphorylation, whereas
  the red blunt-ended lines represent negative regulation (inhibition). IRS-1 = insulin
  receptor substrate 1, PIP2 = phosphatidylinositol-4,5-phosphate, PIP3 = phosphatidylinositol-3,4,5-phosphate,
  PTEN = phosphatase and tensin homolog, PDK1 = phosphoinositide-dependent kinase-1,
  TSC 1/2 = tuberous sclerosis complex 1/2, ATP = adenosine triphosphate, GDP = guanosine
  diphosphate, GTP = guanosine triphosphate, Rheb = Ras homolog enriched in brain,
  4E-BP1 = eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1,
  S6K1 = ribosomal protein S6 kinase beta-1, rpS6 = ribosomal protein S6. The black
  blunt-ended lines indicate the main targets for therapeutic intervention. Created
  with BioRender.com.
papertitle: 'Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.'
reftext: Salihanur Darici, et al. J Clin Med. 2020 Sep;9(9):2934.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9233638
figid_alias: PMC7563273__F3
figtype: Figure
redirect_from: /figures/PMC7563273__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7563273__jcm-09-02934-g003.html
  '@type': Dataset
  description: Targeting the PI3K/Akt/mTOR pathway in AML. The PI3K/Akt/mTOR pathway
    is commonly dysregulated in AML caused by mutations in membrane-bound proteins
    such as receptor tyrosine kinases (RTKs) and small GTPase Ras. Activating mutations
    in fms-like tyrosine kinase 3 (FLT3), such as the FLT3-internal tandem duplication
    (FLT3-ITD), are an important mechanism leading to dysregulation of PI3K/Akt/mTOR
    signaling. The ITD mutation causes ligand-independent activation of the FLT3 receptor,
    leading to constitutive activation of the PI3K/Akt/mTOR pathway. Numerous small-molecule
    inhibitors of this pathway include FLT3 inhibitors (FLT3i), dual PI3K/mTORi, allosteric
    mTORi, pan-class I and isoform-specific PI3Ki, ATP-competitive and allosteric
    Akti, and ATP-competitive mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)
    inhibitors (mTORC1i and mTORC2i). The red arrow indicates elevated Akt phosphorylation,
    whereas the red blunt-ended lines represent negative regulation (inhibition).
    IRS-1 = insulin receptor substrate 1, PIP2 = phosphatidylinositol-4,5-phosphate,
    PIP3 = phosphatidylinositol-3,4,5-phosphate, PTEN = phosphatase and tensin homolog,
    PDK1 = phosphoinositide-dependent kinase-1, TSC 1/2 = tuberous sclerosis complex
    1/2, ATP = adenosine triphosphate, GDP = guanosine diphosphate, GTP = guanosine
    triphosphate, Rheb = Ras homolog enriched in brain, 4E-BP1 = eukaryotic translation
    initiation factor 4E (eIF4E)-binding protein 1, S6K1 = ribosomal protein S6 kinase
    beta-1, rpS6 = ribosomal protein S6. The black blunt-ended lines indicate the
    main targets for therapeutic intervention. Created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PTEN
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - IRS1
  - CUX1
  - SART3
  - PDK1
  - PDPK1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - TSC2
  - TSC1
  - CCL26
  - RHEB
  - RHEBP1
  - MTG1
  - RPTOR
  - EIF4EBP1
  - STK25
  - RPS6KB1
  - EIF4E
  - EIF4E2
  - EIF4E3
  - RPS6
  - Pten
  - Irs1
  - Pdk1
  - Pik3cg
  - Akt1
  - Tsc2
  - Tsc1
  - Rheb
  - Pck1
  - Eif4e
  - Rps6
  - Ecm1
  - Ppp1r13b
  - Pik3ca
  - Pdpk1
  - Pik3r1
  - Eif4ebp1
  - Rps6kb1
  - Tie
  - Ras85D
  - InR
  - Myb
  - Pi3K21B
  - Taf5
  - l(1)G0020
  - Taf4
  - Pi3K92E
  - Rpn2
  - Sap-r
  - Pi3K59F
  - Pi3K68D
  - Akt
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - gig
  - Crtc
  - Thor
  - S6k
  - eIF4E1
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E6
  - eIF4EHP
  - RpS6
  - ATP
  - GDP
  - hematopoiesis
  - myeloid leukemia
---
